What factors do you consider when choosing between vimseltinib and pexidartinib for tenosynovial giant cell tumor (TGCT) patients?  

Pexidartinib has much longer phase 4 follow up data than Vimseltinib. Both drugs have comparable efficacy. The tolerance, especially LFT abnormalities are not an issue with the new lower dose Pexidartinib. The distinguishing factor remains the REMS program. So it is a matter of personal practice/pre...